A 10-Gene Signature to Predict the Prognosis of Early-Stage Triple-Negative Breast Cancer.

ABSTRACT:

Purpose

Triple-negative breast cancer (TNBC) is a particularly challenging subtype of breast cancer, with a poorer prognosis compared to other subtypes. Unfortunately, unlike luminal-type cancers, there is no validated biomarker to predict the prognosis of patients with early-stage TNBC. Accurate biomarkers are needed to establish effective therapeutic strategies.

Materials and methods

In this study, we analyzed gene expression profiles of tumor samples from 184 TNBC patients (training cohort, n=76; validation cohort, n=108) using RNA sequencing.

Results

By combining weighted gene expression, we identified a 10-gene signature (DGKH, GADD45B, KLF7, LYST, NR6A1, PYCARD, ROBO1, SLC22A20P, SLC24A3, and SLC45A4) that stratified patients by risk score with high sensitivity

SUBMITTER: Kim CM 

PROVIDER: S-EPMC11491257 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature